Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins

Journal of Virology

Volumn 87, Issue 23, 2013, Pages 12794-12804

  James, Eddie A ^a   LaFond, Rebecca E ^a,c   Gates, Theresa J ^a   Mai, Duy T ^a   Malhotra, Uma ^b   Kwok, William W ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c MILTENYI BIOTEC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2A; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; YELLOW FEVER VACCINE;

ADULT; ALLELE; ARTICLE; ASIAN; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LONGITUDINAL STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY T LYMPHOCYTE; MOLECULAR RECOGNITION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS STRAIN; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; MALE; MIDDLE AGED; VACCINES, ATTENUATED; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 84887189731     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01160-13     Document Type: Article

References (29)

1. Barrett AD, Higgs S. 2007. Yellow fever:a disease that has yet to be conquered. Annu. Rev. Entomol. 52:209-229.
2. Monath TP. 2005. Yellow fever vaccine. Expert Rev. Vaccines 4:553-574.
3. Monath TP. 2012. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev. Vaccines 11:427-448.
4. Theiler M, Smith HH. 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:787-800.
5. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59:895-900.
6. Niedrig M, Lademann M, Emmerich P, Lafrenz M. 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays:neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health 4:867-871.
7. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL. 2002. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293:151-163.
8. Santos AP, Bertho AL, Dias DC, Santos JR, Marcovistz R. 2005. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. Mem. Inst. Oswaldo Cruz 100:331-337.
9. + T cell responses to smallpox and yellow fever vaccines. Immunity 28:710-722.
10. + T cell response. J. Immunol. 183:7919-7930.
11. Kohler S, Bethke N, Böthe M, Sommerick S, Frentsch M, Romagnani C, Niedrig M, Thiel A. 2012. The early cellular signatures of protective immunity induced by live viral vaccination. Eur. J. Immunol. 42:2363-2373.
12. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, Ljunggren HG, Michaëlsson J, Sandberg JK. 2013. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector-to a memory-type response. J. Immunol. 190: 2150-2158.
13. Santos AP, Matos DC, Bertho AL, Mendonça SC, Marcovistz R. 2008. Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 42:152-155.
14. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, III, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Haddad EK, Sékaly RP. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205:3119-3131.
15. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203:413-424.
16. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10:116-125.
17. de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET. 2013. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and-II binding motifs. PLoS Negl. Trop. Dis. 7:e1938. doi:10.1371/journal.pntd.0001938.
18. Novak EJ, Liu AW, Nepom GT, Kwok WW. 1999. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:R63-R67.
19. + T cell epitopes from complex antigens. J. Immunol. 166:6665-6670.
20. + T cells. J. Allergy Clin. Immunol. 125:1407-1409.
21. + T-cell outcomes during specific immunotherapy. J. Allergy Clin. Immunol. 129:544-551.
22. + T cells directed against H5N1 influenza virus. J. Immunol. 180:1758-1768.
23. Kwok WW, Tan V, Gillette L, Littell CT, Soltis MA, LaFond RB, Yang J, James EA, DeLong JH. 2012. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J. Immunol. 188:2537-2544.
24. Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M. 1986. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 67:229-234.
25. Wrammert J, Miller J, Akondy R, Ahmed R. 2009. Human immune memory to yellow fever and smallpox vaccination. J. Clin. Immunol. 29: 151-157.
26. Martins MA, Silva ML, Marciano AP, Peruhype-Magalhães V, Eloi-Santos SM, Ribeiro JG, Correa-Oliveira R, Homma A, Kroon EG, Teixeira-Carvalho A, Martins-Filho OA. 2007. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever firsttime vaccination:is this the key to prevent severe adverse reactions following immunization? Clin. Exp. Immunol. 148:90-100.
27. Quaresma JA, Barros VL, Pagliari C, Fernandes ER, Andrade HF, Jr, Vasconcelos PF, Duarte MI. 2007. Hepatocyte lesions and cellular immune response in yellow fever infection. Trans. R. Soc. Trop. Med. Hyg. 101:161-168.
28. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R. 2002. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296:117-124.
29. Silva ML, Martins MA, Espírito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, Homma A, Kroon EG, Teixeira-Carvalho A, Elói-Santos SM, Martins-Filho OA. 2011. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29:583-592.